ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Grimont PAD, Grimont F, Farmer JJ, Asbury MA, 1981. Cedecea davisae gen. nov., sp. nov. and Cedecea lapagei sp. nov., new Enterobacteriaceae from clinical specimens. Int J Syst Bacteriol 31: 317–326.
-
2.
Akinosoglou K, Perperis A, Siagris D, Goutou P, Spiliopoulou I, Gogos CA, Marangos M, 2012. Bacteraemia due to Cedecea davisae in a patient with sigmoid colon cancer: a case report and brief review of the literature. Diagn Microbiol Infect Dis 74: 303–306.
-
3.
Cooney S, O’Brien S, Iversen C, Fanning S, 2014. Bacteria: other pathogenic Enterobacteriaceae – Enterobacter and other genera. Motarjemi Y, ed. Encyclopedia of Food Safety. San Diego, CA: Academic Press, 433–441.
-
4.
Davis O, Wall BM, 2006. “Broom straw peritonitis” secondary to Cedecea lapagei in a liver transplant recipient. Perit Dial Int 26: 512–513.
-
5.
Sanchez-Lopez LA, Ibarra BS, de la Garza JAC, Rada F de JMP, Nuñez AIS, López MGR, 2013. First reported case of pneumonia caused by Cedecea lapagei in America. Braz J Infect Dis 17: 626–628.
-
6.
Salazar G, Almeida A, Gómez M, 2013. Cedecea lapagei traumatic wound infection: case report and literature review [in Spanish]. Rev Chilena Infectol 30: 86–89.
-
7.
Hai PD, Dung NM, Tot NH, Chinh NX, Thuyet BT, Hoa LTV, Son PN, Thanh LV, 2020. First report of pneumonia and septic shock caused by Cedecea lapagei in Vietnam. New Microbes New Infect 36: 100698.
-
8.
Ahmad N, Ali SM, Khan AU, 2017. First reported New Delhi metallo-β-lactamase-1-producing Cedecea lapagei. Int J Antimicrob Agents 49: 118–119.
-
9.
García C et al., 2012. Antimicrobial drug resistance in Peru. Emerg Infect Dis 18: 520–521.
-
10.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D, 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
-
11.
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C, 2016. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 75: 40–46.
-
12.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A, 2016. Rayyan – a web and mobile app for systematic reviews. Syst Rev 5: 210.
-
13.
Moola S, Aromataris E & Munn Z JBI Manual for Evidence Synthesis. North Adelaide, Australia: JBI. Available at: https://synthesismanual.jbi.global. Accessed June 05, 2023.
-
14.
Duperret ME, 2020. Sinusitis caused by a rare organism, Cedecea lapagei. BMJ Case Rep 13: e.235331.
-
15.
Ramaswamy VV, Gummadapu S, Suryanarayana N, 2019. Nosocomial pneumonia and sepsis caused by a rare organism Cedecea lapagei in an infant and a review of literature. BMJ Case Rep 12: e229854.
-
16.
Chavez Herrera VR, Rosas De Silva MF, Orendain Alcaraz H, Ceja Espiritu G, Carrazco Peña K, Melnikov V, 2018. Death related to Cedecea lapagei in a soft tissue bullae infection: a case report. J Med Case Reports 12: 328.
-
17.
Kury CMH, Yabrudi AA, de Souza TB, de Souza EC, E Silva Costa LT, Soares CB, Calixto GA, Gramático MR, 2017. First reported case of ventilator-associated pneumonia and sepsis caused by Cedecea lapagei in a Brazilian neonatal intensive care unit. J Pediatric Infect Dis Soc 6: 209–210.
-
18.
Biswal I, Hussain NA, Grover RK, 2015. Cedecea lapagei in a patient with malignancy: report of a rare case. J Cancer Res Ther 11: 646.
-
19.
Hong SK, Lee JS, Kim EC, 2015. First Korean case of Cedecea lapagei pneumonia in a patient with chronic obstructive pulmonary disease. Ann Lab Med 35: 266–228.
-
20.
Yetkin G, Ay S, Kayabaş U, Gedik E, Güçlüer N, Calişkan A, 2008. A pneumonia case caused by Cedecea lapagei [Article in Turkish]. Mikrobiyol Bul 42: 681–684.
-
21.
Dalamaga M, Karmaniolas K, Arsenis G, Pantelaki M, Daskalopoulou K, Papadavid E, Migdalis I, 2008. Cedecea lapagei bacteremia following cement-related chemical burn injury. Burns 34: 1205–1207.
-
22.
Mohamud HA, Mohamud RYH, 2022. Cedecea lapagei an extremely rare uropathogen: a case report. J Pharm Res Int 34: 1–5.
-
23.
Cárdenas JL, 2015. Acute osteomyelitis by Cedecea lapagei. Acta Med Colomb 40: 246–248.
-
24.
Çekin Y, Kızılateş F, Süleyman D, Öztoprak N, Hilmi Çekin A, 2014. The first urinary tract infection caused by Cedecea lapagei: a case report and review of the literature. Gaziantep Med J 20: 193–195.
-
25.
Islam AKS, Bora R, Ahmed R, Borah AK, Ramasamy S, 2016. A case of neonatal sepsis with pneumonia due to Cedecea lapagei. IOSR-JDMS 15: 84–85.
-
26.
Deveci O, Arpag H, 2021. Post-Covid-19 “Cedecea lapagei” pneumonia. Biomed Res Clin Prac 6, doi: 10.15761/BRCP.1000226.
-
27.
González Rivera G, Nava UR, Cano Díalmayer AL, 2022. Reporte de caso en México de neumonía por Cedecea lapagei multidrogorresistente. Respirar 14: 228–233.
-
28.
Arellano Aguilar G, Basurto AL, Luna AG, Esquivel VH, Castilla Barajas JA, 2016. Bacteriemia por Cedecea lapagei. Acta Med Grupo Ángeles 14: 176–178.
-
29.
Falagas ME, Kopterides P, 2006. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64: 7–15.
-
30.
Raman G, Avendano EE, Chan J, Merchant S, Puzniak L, 2018. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 7: 1–14.
-
31.
Alarcón V, Alarcón E, Figueroa C, Mendoza-Ticona A, 2017. Tuberculosis in Peru: epidemiological situation, progress and challenges for its control [Article in Spanish]. Rev Peru Med Exp Salud Publica 34: 299–310.
-
32.
Thompson DK, Sharkady SM, 2020. Expanding spectrum of opportunistic Cedecea infections: current clinical status and multidrug resistance. Int J Infect Dis 100: 461–469.
-
33.
Peretz A, Simsolo C, Farber E, Roth A, Brodsky D, Nakhoul F, 2013. A rare bacteremia caused by Cedecea davisae in patient with chronic renal disease. Am J Case Rep 24: 216–218.
-
34.
Perkins SR, Beckett TA, Bump CM, 1986. Cedecea davisae bacteremia. J Clin Microbiol 24: 675.
-
35.
Ginn PS, Tart SB, Sharkady SM, Thompson DK, 2018. Urinary catheter colonization by multidrug-resistant Cedecea neteri in patient with benign prostatic hyperplasia. Case Rep Infect Dis 2018: 7529526.
-
36.
Ammenouche N, Dupont H, Mammeri H, 2014. Characterization of a novel AmpC β-lactamase produced by a carbapenem-resistant Cedecea davisae clinical isolate. Antimicrob Agents Chemother 58: 6942–6945.
-
37.
Poirel L, Jayol A, Nordmanna P, 2017. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 30: 557.
-
38.
Hong JS, Kim D, Kang DY, Park BY, Yang S, Yoon EJ, Lee H, Jeong SH, 2019. Evaluation of the BD Phoenix M50 Automated Microbiology System for antimicrobial susceptibility testing with clinical isolates in Korea. Microb Drug Resist 25: 1142–1148.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2696 | 1032 | 330 |
| Full Text Views | 408 | 303 | 2 |
| PDF Downloads | 86 | 31 | 1 |
Case Report: Cedecea lapagei Infection: Report of a Case in Peru and Review of the Literature
Ali Al-kassab-Córdova
Ali Al-kassab-Córdova
Centro de Excelencia en Estudios Económicos y Sociales en Salud, Universidad San Ignacio de Loyola, Lima, Peru;
Search for other papers by Ali Al-kassab-Córdova in
Current site
Google Scholar
PubMed
Search for other papers by Ali Al-kassab-Córdova in
Current site
Google Scholar
PubMed
Patricia Valdiviezo-Polo
Patricia Valdiviezo-Polo
Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Peru;
Search for other papers by Patricia Valdiviezo-Polo in
Current site
Google Scholar
PubMed
Search for other papers by Patricia Valdiviezo-Polo in
Current site
Google Scholar
PubMed
Juan R. Ulloque-Badaracco
Juan R. Ulloque-Badaracco
Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Peru;
Search for other papers by Juan R. Ulloque-Badaracco in
Current site
Google Scholar
PubMed
Search for other papers by Juan R. Ulloque-Badaracco in
Current site
Google Scholar
PubMed
Carlos L. Honorio-Arroyo
Carlos L. Honorio-Arroyo
Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Peru;
Hospital de Emergencias José Casimiro Ulloa, Ministerio de Salud, Lima, Peru;
Search for other papers by Carlos L. Honorio-Arroyo in
Current site
Google Scholar
PubMed
Hospital de Emergencias José Casimiro Ulloa, Ministerio de Salud, Lima, Peru;
Search for other papers by Carlos L. Honorio-Arroyo in
Current site
Google Scholar
PubMed
Miguel Hueda-Zavaleta
Miguel Hueda-Zavaleta
Facultad de Ciencias de la Salud, Universidad Privada de Tacna, Tacna, Peru;
Search for other papers by Miguel Hueda-Zavaleta in
Current site
Google Scholar
PubMed
Search for other papers by Miguel Hueda-Zavaleta in
Current site
Google Scholar
PubMed
Vicente A. Benites-Zapata
Vicente A. Benites-Zapata
Maestría de Epidemiología Clínica y Bioestadística, Universidad Científica del Sur, Lima, Peru
Search for other papers by Vicente A. Benites-Zapata in
Current site
Google Scholar
PubMed
Search for other papers by Vicente A. Benites-Zapata in
Current site
Google Scholar
PubMed
ABSTRACT.
Cedecea lapagei is a gram-negative, non-encapsulated, facultative anaerobic bacterium that has been reported in only a few cases with varying clinical presentations, drug susceptibility, and treatment since its first isolation in 1981. This study aimed to describe a case report of C. lapagei in Peru and systematically review the documented case reports of individuals infected with C. lapagei. A 59-year-old man who had become bedridden with Parkinson’s disease and had epilepsy presented with a 1-week history of fever and sore throat and was admitted. Physical examination revealed an obtundation state and abolished vesicular murmur in the right hemithorax. During hospitalization, the patient was diagnosed with various infections, including tuberculosis, for which he received broad-spectrum antibiotics. In the absence of clinical improvement, a urine culture was performed showing C. lapagei (detected by BD Phoenix M50 system, Vernon Hills, IL). The patient received amoxicillin/clavulanate and was discharged. Case reports of C. lapagei were also searched in five databases on January 28, 2023. Twenty cases of C. lapagei were reported worldwide between 2006 and 2022, 16 of which involved adults. Fever was the most common manifestation (75%), and pneumonia was the primary form of presentation (45%). Moreover, 90% of the patients had at least one comorbidity, and 15% died. Also, most of the isolates were sensitive to ciprofloxacin (81%), meropenem (62%), and amikacin (60%). Overall, C. lapagei should be suspected in compromised hosts, particularly those with pneumonia. Although the bacterium can affect various organs and the antibiotic susceptibility pattern is variable, quinolones, tetracyclines, and carbapenems seem to be the first therapeutic option.
- Supplemental Materials (PDF 249 KB)
Author Notes
Written informed consent was provided by the patient for the publication of any potentially identifiable data included in this article.
Authors’ addresses: Ali Al-kassab-Córdova, Centro de Excelencia en Estudios Económicos y Sociales en Salud, Universidad San Ignacio de Loyola, Lima, Peru, E-mail: aliac1998@gmail.com. Patricia Valdiviezo-Polo and Juan R. Ulloque-Badaracco, Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Peru, E-mails: paty_vp12@hotmail.com and ramiroullobada@gmail.com. Carlos L. Honorio-Arroyo, Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Peru, and Hospital de Emergencias José Casimiro Ulloa, Ministerio de Salud, Lima, Peru, E-mail: luishonorio@hotmail.com. Miguel Hueda-Zavaleta, Facultad de Ciencias de la Salud, Universidad Privada de Tacna, Tacna, Peru, E-mail: mighueda@virtual.upt.pe. Vicente A. Benites-Zapata, Maestría de Epidemiología Clínica y Bioestadística, Universidad Científica del Sur, Lima, Peru, E-mail: vbeniteszapata@gmail.com.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Grimont PAD, Grimont F, Farmer JJ, Asbury MA, 1981. Cedecea davisae gen. nov., sp. nov. and Cedecea lapagei sp. nov., new Enterobacteriaceae from clinical specimens. Int J Syst Bacteriol 31: 317–326.
-
2.
Akinosoglou K, Perperis A, Siagris D, Goutou P, Spiliopoulou I, Gogos CA, Marangos M, 2012. Bacteraemia due to Cedecea davisae in a patient with sigmoid colon cancer: a case report and brief review of the literature. Diagn Microbiol Infect Dis 74: 303–306.
-
3.
Cooney S, O’Brien S, Iversen C, Fanning S, 2014. Bacteria: other pathogenic Enterobacteriaceae – Enterobacter and other genera. Motarjemi Y, ed. Encyclopedia of Food Safety. San Diego, CA: Academic Press, 433–441.
-
4.
Davis O, Wall BM, 2006. “Broom straw peritonitis” secondary to Cedecea lapagei in a liver transplant recipient. Perit Dial Int 26: 512–513.
-
5.
Sanchez-Lopez LA, Ibarra BS, de la Garza JAC, Rada F de JMP, Nuñez AIS, López MGR, 2013. First reported case of pneumonia caused by Cedecea lapagei in America. Braz J Infect Dis 17: 626–628.
-
6.
Salazar G, Almeida A, Gómez M, 2013. Cedecea lapagei traumatic wound infection: case report and literature review [in Spanish]. Rev Chilena Infectol 30: 86–89.
-
7.
Hai PD, Dung NM, Tot NH, Chinh NX, Thuyet BT, Hoa LTV, Son PN, Thanh LV, 2020. First report of pneumonia and septic shock caused by Cedecea lapagei in Vietnam. New Microbes New Infect 36: 100698.
-
8.
Ahmad N, Ali SM, Khan AU, 2017. First reported New Delhi metallo-β-lactamase-1-producing Cedecea lapagei. Int J Antimicrob Agents 49: 118–119.
-
9.
García C et al., 2012. Antimicrobial drug resistance in Peru. Emerg Infect Dis 18: 520–521.
-
10.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D, 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
-
11.
McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C, 2016. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 75: 40–46.
-
12.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A, 2016. Rayyan – a web and mobile app for systematic reviews. Syst Rev 5: 210.
-
13.
Moola S, Aromataris E & Munn Z JBI Manual for Evidence Synthesis. North Adelaide, Australia: JBI. Available at: https://synthesismanual.jbi.global. Accessed June 05, 2023.
-
14.
Duperret ME, 2020. Sinusitis caused by a rare organism, Cedecea lapagei. BMJ Case Rep 13: e.235331.
-
15.
Ramaswamy VV, Gummadapu S, Suryanarayana N, 2019. Nosocomial pneumonia and sepsis caused by a rare organism Cedecea lapagei in an infant and a review of literature. BMJ Case Rep 12: e229854.
-
16.
Chavez Herrera VR, Rosas De Silva MF, Orendain Alcaraz H, Ceja Espiritu G, Carrazco Peña K, Melnikov V, 2018. Death related to Cedecea lapagei in a soft tissue bullae infection: a case report. J Med Case Reports 12: 328.
-
17.
Kury CMH, Yabrudi AA, de Souza TB, de Souza EC, E Silva Costa LT, Soares CB, Calixto GA, Gramático MR, 2017. First reported case of ventilator-associated pneumonia and sepsis caused by Cedecea lapagei in a Brazilian neonatal intensive care unit. J Pediatric Infect Dis Soc 6: 209–210.
-
18.
Biswal I, Hussain NA, Grover RK, 2015. Cedecea lapagei in a patient with malignancy: report of a rare case. J Cancer Res Ther 11: 646.
-
19.
Hong SK, Lee JS, Kim EC, 2015. First Korean case of Cedecea lapagei pneumonia in a patient with chronic obstructive pulmonary disease. Ann Lab Med 35: 266–228.
-
20.
Yetkin G, Ay S, Kayabaş U, Gedik E, Güçlüer N, Calişkan A, 2008. A pneumonia case caused by Cedecea lapagei [Article in Turkish]. Mikrobiyol Bul 42: 681–684.
-
21.
Dalamaga M, Karmaniolas K, Arsenis G, Pantelaki M, Daskalopoulou K, Papadavid E, Migdalis I, 2008. Cedecea lapagei bacteremia following cement-related chemical burn injury. Burns 34: 1205–1207.
-
22.
Mohamud HA, Mohamud RYH, 2022. Cedecea lapagei an extremely rare uropathogen: a case report. J Pharm Res Int 34: 1–5.
-
23.
Cárdenas JL, 2015. Acute osteomyelitis by Cedecea lapagei. Acta Med Colomb 40: 246–248.
-
24.
Çekin Y, Kızılateş F, Süleyman D, Öztoprak N, Hilmi Çekin A, 2014. The first urinary tract infection caused by Cedecea lapagei: a case report and review of the literature. Gaziantep Med J 20: 193–195.
-
25.
Islam AKS, Bora R, Ahmed R, Borah AK, Ramasamy S, 2016. A case of neonatal sepsis with pneumonia due to Cedecea lapagei. IOSR-JDMS 15: 84–85.
-
26.
Deveci O, Arpag H, 2021. Post-Covid-19 “Cedecea lapagei” pneumonia. Biomed Res Clin Prac 6, doi: 10.15761/BRCP.1000226.
-
27.
González Rivera G, Nava UR, Cano Díalmayer AL, 2022. Reporte de caso en México de neumonía por Cedecea lapagei multidrogorresistente. Respirar 14: 228–233.
-
28.
Arellano Aguilar G, Basurto AL, Luna AG, Esquivel VH, Castilla Barajas JA, 2016. Bacteriemia por Cedecea lapagei. Acta Med Grupo Ángeles 14: 176–178.
-
29.
Falagas ME, Kopterides P, 2006. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 64: 7–15.
-
30.
Raman G, Avendano EE, Chan J, Merchant S, Puzniak L, 2018. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 7: 1–14.
-
31.
Alarcón V, Alarcón E, Figueroa C, Mendoza-Ticona A, 2017. Tuberculosis in Peru: epidemiological situation, progress and challenges for its control [Article in Spanish]. Rev Peru Med Exp Salud Publica 34: 299–310.
-
32.
Thompson DK, Sharkady SM, 2020. Expanding spectrum of opportunistic Cedecea infections: current clinical status and multidrug resistance. Int J Infect Dis 100: 461–469.
-
33.
Peretz A, Simsolo C, Farber E, Roth A, Brodsky D, Nakhoul F, 2013. A rare bacteremia caused by Cedecea davisae in patient with chronic renal disease. Am J Case Rep 24: 216–218.
-
34.
Perkins SR, Beckett TA, Bump CM, 1986. Cedecea davisae bacteremia. J Clin Microbiol 24: 675.
-
35.
Ginn PS, Tart SB, Sharkady SM, Thompson DK, 2018. Urinary catheter colonization by multidrug-resistant Cedecea neteri in patient with benign prostatic hyperplasia. Case Rep Infect Dis 2018: 7529526.
-
36.
Ammenouche N, Dupont H, Mammeri H, 2014. Characterization of a novel AmpC β-lactamase produced by a carbapenem-resistant Cedecea davisae clinical isolate. Antimicrob Agents Chemother 58: 6942–6945.
-
37.
Poirel L, Jayol A, Nordmanna P, 2017. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 30: 557.
-
38.
Hong JS, Kim D, Kang DY, Park BY, Yang S, Yoon EJ, Lee H, Jeong SH, 2019. Evaluation of the BD Phoenix M50 Automated Microbiology System for antimicrobial susceptibility testing with clinical isolates in Korea. Microb Drug Resist 25: 1142–1148.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2696 | 1032 | 330 |
| Full Text Views | 408 | 303 | 2 |
| PDF Downloads | 86 | 31 | 1 |